Poseida Therapeutics Inc. (PSTX) News
Filter PSTX News Items
PSTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PSTX News Highlights
- PSTX's 30 day story count now stands at 2.
- Over the past 23 days, the trend for PSTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- GENE, RARE and STEM are the most mentioned tickers in articles about PSTX.
Latest PSTX News From Around the Web
Below are the latest news stories about POSEIDA THERAPEUTICS INC that investors may wish to consider to help them evaluate PSTX as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning! |
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate. The Company is investigating P-BCMA-ALLO1 in partnership with Roche for the treatment of relapsed/refractory multiple myeloma |
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining HealthcareThe article embarks on a transformative journey through the biopharmaceutical frontier, where the listed companies stand as titans reshaping healthcare norms. |
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the third quarter ended September 30, 2023. |
Poseida Therapeutics to Present at Two Upcoming Investor ConferencesPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will participate in the following upcoming investor conferences in November: |
Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Poseida Therapeutics, Inc. (PSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Poseida Therapeutics to Present at the 65th ASH Annual Meeting and ExpositionPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the acceptance of three poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held at the San Diego Convention Center in San Diego and virtually on December 9-12, 2023. |
All You Need to Know About Poseida Therapeutics, Inc. (PSTX) Rating Upgrade to BuyPoseida Therapeutics, Inc. (PSTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Poseida Therapeutics Announces Leadership TransitionPoseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Mark Gergen as Executive Chairman and the transition of Kristin Yarema, Ph.D., currently President, Cell Therapy, to the role of President and Chief Executive Officer, each expected to be effective January 1, 2024. |
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors RichAre you looking to invest in biotechnology breakthroughs? |